(via Thenewswire.ca)
OTTAWA, ONTARIO, April 23, 2013 - Avivagen Inc. (TSXV:VIV), a wellness company committed to developing and delivering products that support and improve the health and quality of life for animals and the people who care for them, today announced that it has received TSX Venture Exchange approval to extend the expiry date of 3,975,000 outstanding common share purchase warrants. The Warrants were issued by Avivagen in April and May of 2011 by way of private placement and had expiry dates of April 29, 2013 and May 27, 2013. Each warrant entitles the holder to acquire one common share of Avivagen at a price of $0.10. The expiry date of the warrants has been extended to June 30, 2013. All other terms and conditions of the Warrants will remain unchanged.
The extension of these warrants provides those shareholders with the opportunity to evaluate Avivagen's progress during the next ten weeks. If exercised those warrants would provide further capital to Avivagen without any significant attendant transaction costs or fees. The achievement of long-term financial sustainability continues to be a key goal of Avivagen as it commercializes its products and technologies.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker "VIV". The Company's goal is to develop and deliver scientifically-proven solutions that can truly benefit companion and food animals by taking advantage of natural mechanisms for maintaining optimal health. Avivagen's targeted markets include Pet Wellness and Livestock Productivity.
The company has sites located in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa and Charlottetown, Prince Edward Island.
About OxC-beta
Avivagen's proprietary and patent-protected technology enhances the body's own systems to maintain and improve health, particularly by supporting immune function. Avivagen's commercial technology is Fully-Oxidized Beta-Carotene (OxC-Beta).
OxC-Beta compounds occur naturally in vegetation but in minute amounts. They have been developed to support the health of companion animals and for use in the global food animal market. Research results indicate OxC-beta helps support immune function, which can result in meaningful overall health improvements. In pets, improvements are seen in overall vitality and energy, skin, coat and gastrointestinal wellness. Food Animal benefits include healthier growth, better utilization of feed and decreased mortality.
The first commercial product launched by Avivagen is Oximunol(TM) Chewables for dogs of all ages
About Oximunol(TM) Chewables - "Optimized Health in a Chewable Tablet"
Oximunol(TM) is a scientifically-formulated chewable tablet containing Avivagen's proprietary, patented active ingredient, OxC-beta. Oximunol(TM) Chewables are currently available for dogs of all ages in the United States, working with a dog's own immune system to optimize overall health and well-being.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
More information can be found at www.avivagen.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
Avivagen Inc.
Cameron Groome
Phone: 613-949-8164
c.groome@avivagen.com
Copyright (c) 2013 TheNewswire - All rights reserved.